Keywords: Pfizer, Torisel, Ph III, Renal cell cancer, Bayer, Nexavar

Pfizer's Torisel fails in Ph III advanced renal cell cancer study

Article | 17 May 2012

Print This

There was disappointment for global pharma behemoth Pfizer (NYSE: PFE) when it said that the Phase III INTORSECT (B1771003) study, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in